These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


843 related items for PubMed ID: 18370236

  • 1. Pharmacogenomics in Alzheimer's disease.
    Cacabelos R.
    Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
    [Abstract] [Full Text] [Related]

  • 2. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R.
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [Abstract] [Full Text] [Related]

  • 3. Influence of pharmacogenetic factors on Alzheimer's disease therapeutics.
    Cacabelos R.
    Neurodegener Dis; 2008 Jul; 5(3-4):176-8. PubMed ID: 18322383
    [Abstract] [Full Text] [Related]

  • 4. Pharmacogenomics and therapeutic strategies for dementia.
    Cacabelos R.
    Expert Rev Mol Diagn; 2009 Sep; 9(6):567-611. PubMed ID: 19732004
    [Abstract] [Full Text] [Related]

  • 5. Pharmacogenomics and therapeutic prospects in Alzheimer's disease.
    Cacabelos R.
    Expert Opin Pharmacother; 2005 Oct; 6(12):1967-87. PubMed ID: 16197352
    [Abstract] [Full Text] [Related]

  • 6. Pharmacogenomics and therapeutic prospects in dementia.
    Cacabelos R.
    Eur Arch Psychiatry Clin Neurosci; 2008 Mar; 258 Suppl 1():28-47. PubMed ID: 18344047
    [Abstract] [Full Text] [Related]

  • 7. Genomics and phenotypic profiles in dementia: implications for pharmacological treatment.
    Cacabelos R, Fernández-Novoa L, Corzo L, Pichel V, Lombardi V, Kubota Y.
    Methods Find Exp Clin Pharmacol; 2004 Mar; 26(6):421-44. PubMed ID: 15349138
    [Abstract] [Full Text] [Related]

  • 8. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.
    Cacabelos R.
    Mol Diagn Ther; 2007 Mar; 11(6):385-405. PubMed ID: 18078356
    [Abstract] [Full Text] [Related]

  • 9. The application of functional genomics to Alzheimer's disease.
    Cacabelos R.
    Pharmacogenomics; 2003 Sep; 4(5):597-621. PubMed ID: 12943467
    [Abstract] [Full Text] [Related]

  • 10. Pharmacogenomic protocols in CNS disorders and dementia.
    Cacabelos R.
    Neurodegener Dis; 2010 Sep; 7(1-3):167-9. PubMed ID: 20197699
    [Abstract] [Full Text] [Related]

  • 11. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.
    Cacabelos R, Llovo R, Fraile C, Fernández-Novoa L.
    Curr Alzheimer Res; 2007 Sep; 4(4):479-500. PubMed ID: 17908053
    [Abstract] [Full Text] [Related]

  • 12. Molecular genetics of Alzheimer's disease and aging.
    Cacabelos R, Fernandez-Novoa L, Lombardi V, Kubota Y, Takeda M.
    Methods Find Exp Clin Pharmacol; 2005 Jul; 27 Suppl A():1-573. PubMed ID: 16470248
    [Abstract] [Full Text] [Related]

  • 13. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
    Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW.
    Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
    [Abstract] [Full Text] [Related]

  • 14. Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease.
    Blesa R, Aguilar M, Casanova JP, Boada M, Martínez S, Alom J, de la Hoz CH, Sancho J, Fernández O, Gil-Neciga E, Massó JF.
    Alzheimer Dis Assoc Disord; 2006 Feb; 20(4):248-54. PubMed ID: 17132969
    [Abstract] [Full Text] [Related]

  • 15. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K.
    Neurosci Lett; 2008 Aug 01; 440(2):145-9. PubMed ID: 18555606
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. ApoE genotype accounts for the vast majority of AD risk and AD pathology.
    Raber J, Huang Y, Ashford JW.
    Neurobiol Aging; 2004 Aug 01; 25(5):641-50. PubMed ID: 15172743
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Genomics and pharmacogenomics of dementia.
    Cacabelos R, Martínez-Bouza R.
    CNS Neurosci Ther; 2011 Oct 01; 17(5):566-76. PubMed ID: 20718828
    [Abstract] [Full Text] [Related]

  • 20. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease.
    Seripa D, Bizzarro A, Pilotto A, D'onofrio G, Vecchione G, Gallo AP, Cascavilla L, Paris F, Grandone E, Mecocci P, Santini SA, Masullo C, Pilotto A.
    Pharmacogenet Genomics; 2011 Apr 01; 21(4):225-30. PubMed ID: 20859244
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 43.